Differentiating Hedgehog Pathway Inhibitors in Locally Advanced Basal Cell Carcinoma
Without a formal staging system, advanced basal cell carcinoma is defined by the interplay of tumor size, anatomic site, depth, histology, and host factors that may not be apparent on initial biopsy.
Although hedgehog pathway inhibitors are considered first-line systemic therapy for locally advanced disease, surgical fatigue and patient preference may warrant earlier discussion of oral treatment than current practice patterns reflect.

Multimodal planning for advanced basal cell carcinoma extends beyond labeled indications, with neoadjuvant hedgehog inhibition, adjuvant radiation, and immune checkpoint inhibitors each occupying a defined place in treatment sequencing.

Distinct pharmacokinetic profiles, including volume of distribution, half-life, and time to steady state, differentiate the two approved hedgehog inhibitors and can be translated into patient-facing counseling during shared decision-making.

Class-wide laboratory monitoring, a predictable adverse event timeline, and emerging resistance mechanisms shape how hedgehog inhibitor therapy is initiated, sustained, and eventually complemented by agents in development.

For a functional older patient with recurrent, infiltrative disease after repeated excisions, multidisciplinary review supports hedgehog inhibition with curative intent and a potential path toward less morbid definitive treatment.

Long-term response data, trial response criteria, a structured laboratory schedule, and symptom-specific supportive care together determine whether patients can remain on hedgehog inhibitor therapy long enough to benefit.

When a patient prioritizes preserving taste and independence, differences in plasma protein binding, tissue distribution, and real-world tolerability become central considerations in selecting among hedgehog pathway inhibitors.

Divergent response definitions across pivotal trials complicate cross-trial comparison, and resistance mechanisms that may be shared across the class inform sequencing toward PD-1 inhibition after hedgehog inhibitor failure.

After repeated surgery and radiation have failed, systemic hedgehog inhibition offers a path toward disease control, with pivotal and real-world vismodegib data guiding expectations for response, duration, and tolerability.

Gaurav Singh, MD, MPH, explains how pharmacokinetics, trial design, and real-world tolerability set sonidegib apart from vismodegib in locally advanced basal cell carcinoma and when to start systemic therapy earlier.